Date	e: 10/18/2023			
	Name:_ Ishan Shah			
Hun	nuscript Title: Osteobiolo nan Bone Morphogenetic nuscript number (if known):	Proteins - A Narrative R	ine Disease: Current Clinical Applications of Recombinateview	nt
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content c ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.	
	following questions apply t uscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to th	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	em #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other items,	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None		
		Time fue mee	at 26 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	St 36 Months	
3	Royalties or licenses	x_None		

None

3

Consulting fees

5	Payment or honoraria for lectures, presentations, speakers bureaus,	x_None	
	manuscript writing or educational events		
6	Payment for expert testimony	x_None	
7	Support for attending meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or pending	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or Advisory Board		
10	=	Nana	
10	Leadership or fiduciary role in other board, society,	x_None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	x_None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
N	lone		

Please place an "X" next to the following statement to indicate your agreement:

Date	e: 10/18/2023		
You	r Name:_ Manat Chopra		
Mar	nuscript Title: Osteobiolo	gics in Degenerative Spi	ine Disease: Current Clinical Applications of Recombinar
Hur	nan Bone Morphogenetic	Proteins - A Narrative R	eview
	nuscript number (if known):		
rela part to ti	ted to the content of your nies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply touscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to tl	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	x_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		- :	
2		Time frame: pas	t 36 months
2	Consider an analysis of the second	Nama	
	Grants or contracts from	xNone	
	any entity (if not indicated	x_None	
3	any entity (if not indicated in item #1 above).		
3	any entity (if not indicated	x_None	

Consulting fees

_None

5	Payment or honoraria for lectures, presentations, speakers bureaus,	x_None	
	manuscript writing or educational events		
6	Payment for expert testimony	x_None	
7	Support for attending meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or pending	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or Advisory Board		
10	=	Nana	
10	Leadership or fiduciary role in other board, society,	x_None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	x_None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
N	lone		

Please place an "X" next to the following statement to indicate your agreement:

Date	e: 10/18/2023		
	r Name:_ Andy Ton		
Maı	nuscript Title: Osteobiolo	gics in Degenerative Spi	ne Disease: Current Clinical Applications of Recombinar
Hui	nan Bone Morphogenetic	Proteins - A Narrative Re	eview
Maı	nuscript number (if known):		
rela part to to rela The mar The to to	ted to the content of your name ies whose interests may be ransparency and does not not itionship/activity/interest, it following questions apply to auscript only. author's relationships/activity epidemiology of hypertendication, even if that medications are supply to the epidemiology of hypertendication, even if that medications.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. it is preferable that you do to the author's relationship vities/interests should be go nsion, you should declare a tion is not mentioned in the	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	I planning of the work
1	All support for the present		n planning of the work
1	manuscript (e.g., funding,	x_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2	Country on south 1. C	Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated	xNone	
	in item #1 above).		
3	Royalties or licenses	x_None	
J	no junios or meerises	A_ITOTIC	
4	Consulting fees	x_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	x_None	
	manuscript writing or educational events		
6	Payment for expert testimony	x_None	
7	Support for attending meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or pending	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or Advisory Board		
10	=	Nana	
10	Leadership or fiduciary role in other board, society,	x_None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	x_None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
N	lone		

Please place an "X" next to the following statement to indicate your agreement:

Date:	10/18/2023
Your	Name:_ Raymond J. Hah
Manu	script Title: Osteobiologics in Degenerative Spine Disease: Current Clinical Applications of Recombinan
Huma	an Bone Morphogenetic Proteins - A Narrative Review
Manu	script number (if known):
	• • • • • • • • • • • • • • • • • • • •

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	A.I	Time frame: Since the initial	planning of the work
1	All support for the present	x_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	SI bone	Research support
	any entity (if not indicated		* 1
	in item #1 above).		
3	Royalties or licenses	x_None	
4	Consulting fees	_ Nuvasive	50,000

5	Payment or honoraria for	x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x_None	
	testimony		
7	Support for attending	North American Spine	
	meetings and/or travel	Society	
8	Patents planned, issued or	x None	
	pending		
	. 5		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x_None	
	financial interests		
DI		COLUMN CO	landa a ban

Please summarize the above conflict of interest in the following box:

Raymond J. Hah has received grant funding from SI bone, consulting fees from NuVasive, and support from the North American Spine Society to attend meetings.

Please place an "X" next to the following statement to indicate your agreement:

Date: 10/18/2023
Your Name:_ Jeffrey C. Wang
Manuscript Title: Osteobiologics in Degenerative Spine Disease: Current Clinical Applications of Recombinant
Human Bone Morphogenetic Proteins - A Narrative Review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastx_None	36 months
3	Royalties or licenses	Biomet Novapproach Seaspine Synthes	IP Royalties IP Royalties IP Royalties IP Royalties
4	Consulting fees	x_None	

		1	
5	Doumant or hangraria for	y None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	x_None	
	manuscript writing or		
	educational events		
6	Payment for expert testimony	x_None	
7	Support for attending meetings and/or travel	x_None	
	Datasta slave al Sacradas	Niere	
8	Patents planned, issued or pending	xNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	
10	Leadership or fiduciary role in other board, society,	AO Foundation	Board or Committee Member
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	Dono Diologica	
11	·	Bone Biologics	
		Electrocore	
		PearlDiver	
12		Surgitech	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	xNone	
	services		
13	Other financial or non- financial interests	x_None	

Please summarize the above conflict of interest in the following box:

Jeffrey C. Wang has received intellectual property royalties from Zimmer Biomet, NovApproach, SeaSpine, and DePuy Synthes, and is a committee member of AO Foundation. He holds stocks in the Bone Biologics, Electrocore, PearlDiver and Surgitech.

Please place an "X" next to the following statement to indicate your agreement:

Date:10/18/2023				
Your Name: Ram K. Alluri				
Manuscript Title: Osteobiologics in Degenerative Spine Disease: Current Clinical Applications of Recombinant				
Human Bone Morphogenetic Proteins - A Narrative Review				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None			
Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	NIH			
3	Royalties or licenses	None			
4	Consulting fees	HIA Technologies			

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	Eccential Robotics Med-legal consulting	
	testimony	(not testimony)	
7	Support for attending meetings and/or travel	USC	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	_ HIA Technologies	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	Alphatec Spine	Research Support

Please summarize the above conflict of interest in the following box:

Ram K. Alluri has received grant funding from NIH, consulting fees from HIA Technologies, payment from Eccentrial Robotics for lectures and presentations, payment for expert testimony from Med-legal consulting (not testimony), support for attending meetings from USC, research support from Alphatec Spine, and holds stocks in the HIA Technologies.

Please place an "X" next to the following statement to indicate your agreement: